{
  "@graph" : [ {
    "@id" : "mas_evidence_types:Audit%20reports",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Other%20evidence",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Audit reports"
    }
  }, {
    "@id" : "mas_evidence_types:CONCEPT-Evidence_type",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Evidence type"
    }
  }, {
    "@id" : "mas_evidence_types:CONCEPT-Guidance_and_advice",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:CONCEPT-Evidence_type",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Guidance and advice"
    }
  }, {
    "@id" : "mas_evidence_types:CONCEPT-Media_and_commentaries",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Media%20and%20commentaries",
    "definition" : "Media: Press releases and media news stories relevant to health care provision in the NHS, i.e. addressing a disease or condition or describe a situation that may affect clinical staff or senior managers.<br />To also include promotion of updated NICE guidance and quality standards linking to the update / change page e.g. http://www.nice.org.uk/guidance/qs10/chapter/Update-information.<br />Commentaries: Editorial, review and comment articles from journals. Media and commentaries content is to be included to cover one of the following purposes:<br />&bull; Health news stories in the popular media to allow clinical staff to anticipate patient queries and misconceptions and identify the evidence-based responses e.g. BBC Health News, Behind the Headlines from NHS Choices<br />&bull; Organisational draft publications and consultations, news feeds and press releases to stay abreast of new or pending developments and publications. For example, developments in the NHS, the pharmaceutical industry, and elsewhere may affect NHS professionals without producing, or before they produce more formal documents; NICE Appraisal Consultation Documents<br />&bull; Topical news stories and press releases from key organisational websites raise awareness of issues that may have an early impact on their work. These include:<br />o &lsquo;Latest News&rsquo; sections from key NHS, government and pharmacy sites e.g. National Audit Commission, Care Quality Commission, Health Protection Agency;<br />o Organisational commentary on previously published / bibliographic evidence e.g. the British Medical Association; Department of Health and Social Care statements on pharmacy, medicines, prescribing and major NHS issues.<br />o New trials, licence indications and product launches in the UK and significant EU marketing authorisation from manufacturers press releases, Medicines and Healthcare products Regulatory Agency and European Medicines Agency.<br />&bull; News agencies, for example BBC Health News and Reuters Health, are to be reviewed daily for key research and trials highlighted by national newspapers including those where the abstract or full text isn&rsquo;t available. NB: Where possible the record needs to link to original source; news agency can be included under &lsquo;related URL&rsquo; field if appropriate<br />&bull; Editorials, selected (non-systematic) reviews and guidelines which help contextualise new trials, new license indications, product launches or medicine-related developments in the treatment of particular diseases.<br />NB: Media and commentaries content will only be available via the NICE Evidence Search for three months from publication. (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Media and commentaries"
    }
  }, {
    "@id" : "mas_evidence_types:CONCEPT-Policy",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Policy",
    "definition" : "UK government health policy with a direct relevance to medicines and prescribing. For example, policy frameworks and consultation on legislation changes relevant to medicines from the Department of Health and the NHS England. (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Policy"
    }
  }, {
    "@id" : "mas_evidence_types:CONCEPT-Safety_alerts",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Safety%20alerts",
    "definition" : "Safety alerts and recalls content covering UK drug withdrawals, and patient safety and medical device alerts where relevant to medicines and prescribing, from the Medicines and Healthcare products Regulatory Agency.<br />Safety and alerting information from key international regulatory sources with a relevance to UK practice, for example, European Medicines Agency and US Food and Drug Administration. (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Safety alerts"
    }
  }, {
    "@id" : "mas_evidence_types:CONCEPT-Safety_support_material",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Safety%20alerts",
    "definition" : "Other safety materials. [ie other than safety alerts] (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Safety support material"
    }
  }, {
    "@id" : "mas_evidence_types:Drug%20best%20practice%20guidance",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:CONCEPT-Guidance_and_advice",
    "definition" : "Other newly published or updated guidance and recommendations to support the optimal use of medicines from national organisations producers relevant to UK practice, including advice from the Scottish Medicines Consortium and All Wales Medicines Strategy Group. (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Drug best practice guidance"
    }
  }, {
    "@id" : "mas_evidence_types:Drug%20prescribing",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:CONCEPT-Guidance_and_advice",
    "definition" : "Technical information to support the safer prescribing of medicines, including British National Formulary drug monograph updates and significant product licence changes from the electronic Medicines Compendium. NB: Product licence changes may be identified from manufacturers but need to link to Summary of Product Characteristics listed by the electronic Medicines Compendium. (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Drug prescribing"
    }
  }, {
    "@id" : "mas_evidence_types:Drug%2Fmedicines%20management",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Other%20evidence",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Drug/medicines management"
    }
  }, {
    "@id" : "mas_evidence_types:Effective%20practice%20examples",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Other%20evidence",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Effective practice examples"
    }
  }, {
    "@id" : "mas_evidence_types:Evidence%20summaries",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Evidence%20summary",
    "definition" : "Summaries of the best available evidence related to medicines and prescribing including clinical review articles, NIHR Signals and the MPT evidence summaries designed to meet demand for information to inform local NHS planning and decision-making. (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Evidence summaries"
    }
  }, {
    "@id" : "mas_evidence_types:Evidence%20summary",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:CONCEPT-Evidence_type",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Evidence summaries"
    }
  }, {
    "@id" : "mas_evidence_types:Guidance",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:CONCEPT-Guidance_and_advice",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Guidance"
    }
  }, {
    "@id" : "mas_evidence_types:Learning%20materials",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Other%20evidence",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Learning materials"
    }
  }, {
    "@id" : "mas_evidence_types:MAS_evidence_type",
    "@type" : "http://www.w3.org/2004/02/skos/core#ConceptScheme",
    "hasTopConcept" : "mas_evidence_types:CONCEPT-Evidence_type",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "MAS evidence type"
    }
  }, {
    "@id" : "mas_evidence_types:Media%20and%20commentaries",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:CONCEPT-Evidence_type",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Media and commentaries"
    }
  }, {
    "@id" : "mas_evidence_types:Medicines%20Q%20%26%20A",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Evidence%20summary",
    "definition" : "SPS produced evidence-based, quality assured answers to selected medicines-related enquires made to local medicines information services. (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Medicines Q&A"
    }
  }, {
    "@id" : "mas_evidence_types:Other%20economic%20evaluations",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Other%20evidence",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Health economics"
    }
  }, {
    "@id" : "mas_evidence_types:Other%20evidence",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:CONCEPT-Evidence_type",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Other evidence"
    }
  }, {
    "@id" : "mas_evidence_types:Other%20primary%20research",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Primary%20research",
    "definition" : "Newly published or updated primary research which is not a RCT or ongoing or unpublished research, for example, observational, cohort, and case control studies. Post-hoc analyses of clinical trials are to only be included where regarding conditions and diseases relevant to UK clinical practice, and where the analysis adds important information. (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Other primary research"
    }
  }, {
    "@id" : "mas_evidence_types:Patient%20information",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Other%20evidence",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Patient information"
    }
  }, {
    "@id" : "mas_evidence_types:Policy",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:CONCEPT-Evidence_type",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Policy"
    }
  }, {
    "@id" : "mas_evidence_types:Population%20intelligence",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Other%20evidence",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Population intelligence"
    }
  }, {
    "@id" : "mas_evidence_types:Population%20needs%20assessment",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Other%20evidence",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Population needs assessments"
    }
  }, {
    "@id" : "mas_evidence_types:Primary%20research",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:CONCEPT-Evidence_type",
    "definition" : "To support evidence-based practice, content in these categories is to cover primary research into medicines (or lifestyle interventions involving medicines) relating to conditions and diseases relevant to UK clinical practice.<br />To support this as awareness raising service, journals and database sources are to be included where the content is:<br />&bull; Open access full text e.g. Cochrane, PLOS Medicine<br />&bull; Full text via NHS OpenAthens authentication (national content only) e.g. Lancet<br />&bull; Freely available abstract.<br />NB: The MAS should link to full text where freely available. For gated full text please link to abstract. Highlighting an abstract of a paper is sufficient to raise awareness and allows the user to request or pursue further information/ access if required.<br />NB: News agencies, for example Reuters Health, may highlight key primary research content.<br />No journal is excluded. Journals included on the SOP source list and checked daily have been identified by SPS as the key journals featuring key medicine-related studies, including the Big 5 &ndash; the Lancet, the Journal of the American Medical Association, the British Medical Journal, Annals of Internal Medicines and the New England Journal of Medicine. (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Primary research"
    }
  }, {
    "@id" : "mas_evidence_types:Quality%20measures",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Other%20evidence",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Quality measures"
    }
  }, {
    "@id" : "mas_evidence_types:Randomised%20controlled%20trials",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Primary%20research",
    "definition" : "Phase 2 and 3 randomised controlled trails relevant to medicines and prescribing, for example studies of new drugs, new studies of established drugs and post-marketing studies that improve knowledge about safety profile of established drugs. Phase 2 RCTs where:<br />&bull; the study sample is relatively large considering the disease/condition (smaller studies can be considered in rare diseases relevant to UK clinical practice)<br />&bull; the study investigates new drugs where the condition is not already successfully treated by a drug.<br />NB: Uncontrolled Phase 2 studies may be considered for inclusion in exceptional circumstances. (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Randomised controlled trials"
    }
  }, {
    "@id" : "mas_evidence_types:Safety%20alerts",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:CONCEPT-Evidence_type",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Safety alerts"
    }
  }, {
    "@id" : "mas_evidence_types:Systematic%20review",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:CONCEPT-Evidence_type",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Systematic reviews and meta-analyses"
    }
  }, {
    "@id" : "mas_evidence_types:Systematic%20reviews",
    "@type" : "http://www.w3.org/2004/02/skos/core#Concept",
    "broader" : "mas_evidence_types:Systematic%20review",
    "definition" : "Newly published or updated systematic reviews and health technology assessments relating to medicines and prescribing for conditions and diseases relevant to UK clinical practice.<br />Systematic reviews/ meta-analysis of medicines or lifestyle interventions, for example, the Cochrane Database of Systematic Reviews and those published by a journal which conforms to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard. Systematic reviews from other journals are deemed reliable if the abstract reports the inclusion/exclusion criteria, confirms two or more sources have been searched, and incorporates a synthesis of included studies. NB: Cochrane content is to be limited to systematic reviews with specific relevance to medicines awareness. (NICE Medicines Awareness Content Strategy v4.0)",
    "prefLabel" : {
      "@language" : "en",
      "@value" : "Systematic reviews"
    }
  }, {
    "@id" : "urn:x-evn-master:mas_evidence_types",
    "@type" : "owl:Ontology",
    "status" : "metadata:UnderDevelopmentStatus",
    "defaultNamespace" : "http://nice.org.uk/MAS/evidence_type/",
    "newInstancesUserCannotModifyURI" : "0",
    "comment" : "A list of evidence types includes in the Medicines Awareness Service",
    "label" : "MAS evidence types",
    "imports" : [ "http://topbraid.org/skos.shapes", "http://topbraid.org/imported", "urn:x-evn-master:edg_enumerations_singleton" ]
  } ],
  "@context" : {
    "prefLabel" : {
      "@id" : "http://www.w3.org/2004/02/skos/core#prefLabel"
    },
    "broader" : {
      "@id" : "http://www.w3.org/2004/02/skos/core#broader",
      "@type" : "@id"
    },
    "definition" : {
      "@id" : "http://www.w3.org/2004/02/skos/core#definition",
      "@type" : "http://www.w3.org/1999/02/22-rdf-syntax-ns#HTML"
    },
    "imports" : {
      "@id" : "http://www.w3.org/2002/07/owl#imports",
      "@type" : "@id"
    },
    "status" : {
      "@id" : "http://topbraid.org/metadata#status",
      "@type" : "@id"
    },
    "label" : {
      "@id" : "http://www.w3.org/2000/01/rdf-schema#label"
    },
    "newInstancesUserCannotModifyURI" : {
      "@id" : "http://topbraid.org/teamwork#newInstancesUserCannotModifyURI",
      "@type" : "http://www.w3.org/2001/XMLSchema#boolean"
    },
    "comment" : {
      "@id" : "http://www.w3.org/2000/01/rdf-schema#comment"
    },
    "defaultNamespace" : {
      "@id" : "http://topbraid.org/swa#defaultNamespace"
    },
    "hasTopConcept" : {
      "@id" : "http://www.w3.org/2004/02/skos/core#hasTopConcept",
      "@type" : "@id"
    },
    "metadata" : "http://topbraid.org/metadata#",
    "rdf" : "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "owl" : "http://www.w3.org/2002/07/owl#",
    "teamwork" : "http://topbraid.org/teamwork#",
    "mas_evidence_types" : "http://nice.org.uk/MAS/evidence_type/",
    "rdfs" : "http://www.w3.org/2000/01/rdf-schema#"
  }
}
